Generating robust, durable and effective tumor antigen (Ag)-specific CD8+ T cells that are competent to eradicate primary tumors and tumor metastases or to prevent disease recurrence as a consequence of active specific vaccines has proven clinically difficult.1 The gene discussed is CD8A; the disease is neoplasm.